INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST

NCATS 基因治疗测试的体内和离体免疫原性分析

• 批准号: 10891948
• 负责人: max moore
• 金额: $ 44.26万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-03 至 2026-07-02
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10891948
• 关键词: INSILICO; EX; VIVO; IMMUNOGENICITY; ANALYSIS

The Therapeutic Development Branch (TDB) in the Division of Preclinical Innovation (DPI) of NCATS advances novel therapeutics and technologies through preclinical and clinical stages of development. TDB initiated NCATS’ collaborative Rare Disease Platform Vector Gene Therapy (PaVe-GT) program. The program involves preclinical development and clinical evaluation of gene therapy products for rare diseases. In-silico and Ex-vivo analysis of the candidates is essential in de-risking the potential failure of the candidate in human subjects.

NCATS临床前创新（DPI）的治疗发展分支（TDB）通过临床前和临床阶段进行新的疗法和技术。 TDB启动了NCAT的合作稀有疾病平台媒介基因治疗（PAVE-GT）计划。该计划涉及对罕见疾病的基因治疗产物的临床前开发和临床评估。对候选人的silico和前体体分析对于降低候选人在人类受试者中的潜在失败至关重要。